Senti Biosciences gets Nasdaq noncompliance notice; trading continues
Senti Biosciences Holdings received Nasdaq notices for failing the $1.00 minimum bid price and $2.5 million stockholders’ equity requirements for the Nasdaq Capital Market. Trading continues under SNTI, with until Feb 23, 2027 to regain bid-price compliance.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.